Moss Adams Wealth Advisors LLC Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Moss Adams Wealth Advisors LLC lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 434 shares of the biopharmaceutical company’s stock after purchasing an additional 15 shares during the period. Moss Adams Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $456,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Sachetta LLC raised its position in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares in the last quarter. Stephens Consulting LLC bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $26,000. West Paces Advisors Inc. lifted its stake in Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares during the period. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth about $28,000. Finally, Lynx Investment Advisory purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $33,000. Institutional investors own 83.31% of the company’s stock.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.48% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on REGN. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, September 16th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $1,200.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, September 23rd. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Piper Sandler raised their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research report on Friday, August 23rd. Finally, Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,116.00.

Regeneron Pharmaceuticals Stock Down 0.8 %

Regeneron Pharmaceuticals stock opened at $990.68 on Friday. The business’s 50-day simple moving average is $1,109.58 and its two-hundred day simple moving average is $1,039.79. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The company has a market cap of $109.21 billion, a PE ratio of 26.24, a PEG ratio of 3.45 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter in the prior year, the firm earned $8.79 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% on a year-over-year basis. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.85 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.